Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparQuinto: Bevacizumab, Everolimus, and Lapatinib in Neoadjuvant Breast Cancer
NCT00567554Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Oct 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, everolimus and lapatinib in breast cancer (6 arms), sponsored by GBG Forschungs. Primary endpoint: Pathologic Complete Response at 24 weeks. Started Oct 2007; status: completed.
02
Drugs
bevacizumabeverolimuslapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00567554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567554.